IsoPlexis - About the company
IsoPlexis is an acquired company based in New Haven (United States), founded in 2012 by Sean Mackay. It operates as a Developer of multiplexed single-cell analysis tools for the diagnostics and life science research. IsoPlexis has raised $186M in funding from investors like YEI Innovation Fund, Northpond Ventures and Connecticut Innovations, with last known valuation of $*****. The company has 540 active competitors, including 154 funded and 108 that have exited. Its top competitors include companies like Natera, 10X Genomics and Guardant Health.
Company Details
Developer of multiplexed single-cell analysis tools for diagnostics and life science research. Their specialties include 'secretome analysis for applications in immune monitoring, vaccine response evaluation, personalized medicine, adoptive immune therapies, stem cell research, and oncology.
- Website
- isoplexis.com
- Registered Address
- Branford, Connecticut
Key Metrics
Founded Year
2012
Location
New Haven, United States
Stage
Acquired
Total Funding
$186M in 16 rounds
Latest Funding Round
Last Known Valuation
$***** as on Dec 21, 2022
Investors
Ranked
36th among 540 active competitors
Annual Revenue
$10M - $50M as on Dec 31, 2022
Employee Count
52 as on Mar 04, 2025
Exit Details
Acquired by Berkeley Lights (Dec 21, 2022)
Legal entities associated with IsoPlexis
IsoPlexis is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
ISOPLEXIS CORP CIN: 1615055 , United States, Active | Feb 28, 2013 | $10M - $50M (As on Dec 31, 2022) | - | - |
Isoplexis Corporation CIN: 462179799 , United States, Active | Dec 31, 2011 | - | 261 (As on Dec 31, 2022) | - |
IsoPlexis's acquisition details
IsoPlexis got acquired by Berkeley Lights on Dec 21, 2022.
Click here to take a look at IsoPlexis's acquisition in detail
Sign up to download IsoPlexis' company profile
IsoPlexis's funding and investors
IsoPlexis has raised a total funding of $186M over 16 rounds. Its first funding round was on Jun 10, 2014. Its latest funding round was a Conventional Debt round on Jan 07, 2021 for $*****. 3 investors participated in its latest round. IsoPlexis has 16 institutional investors.
Here is the list of recent funding rounds of IsoPlexis:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 07, 2021 | 4715991 | Conventional Debt | 5074446 | 1154397 | 6375504 | 5700933 |
Jan 07, 2021 | 9810258 | Series D | 9073409 | 2572533 | 6460867 | |
Jun 09, 2020 | 9264414 | Grant (prize money) | 7362062 | 8800450 | 1695983 |
Access funding benchmarks and valuations. Sign up today!View details of IsoPlexis's funding rounds and investors
IsoPlexis' founders and board of directors
Founder? Claim ProfileThe founders of IsoPlexis is Sean Mackay.
Here are the details of IsoPlexis' key team members:
- Sean Mackay: Co-Founder & CEO of IsoPlexis.
View details of IsoPlexis's Founder profiles and Board Members
IsoPlexis' employee count trend
IsoPlexis has 52 employees as of Mar 25. Here is IsoPlexis's employee count trend over the years:
Uncover IsoPlexis' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
IsoPlexis's Competitors and alternates
Top competitors of IsoPlexis include Natera, 10X Genomics and Guardant Health. Here is the list of Top 10 competitors of IsoPlexis, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Natera 2004, Redwood City (United States), Public | Developer of cell-free DNA testing for oncology, women’s health, and organ health | $152M | 77/100 | |
2nd | 10X Genomics 2012, Pleasanton (United States), Public | Developer of single-cell, spatial, and in situ tools for high-resolution biological analysis | $243M | 77/100 | |
3rd |  Guardant Health 2012, Redwood City (United States), Public | Developer of digital sequencing technology for cancer detection | $557M | 75/100 | |
4th | Foundation Medicine 2010, Cambridge (United States), Acquired | Provider of genomics-based diagnostics test for cancer | $96.5M | 70/100 | |
5th | Online platform for genetic and diagnostic health testing that helps identify health risks | $67.6M | 69/100 | ||
6th | BillionToOne 2015, San Francisco (United States), Public | Provider of cell-free cancer liquid biopsy test | $389M | 69/100 | |
7th | Myriad Genetics 1991, United States, Public | Developer of molecular diagnostics and personalized medicine for cancer | - | 68/100 | |
8th |  Foresight Diagnostics 2020, Aurora (United States), Acquired | Developer of minimally-invasive liquid biopsy test for the detection of cancer | $104M | 66/100 | |
9th | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 66/100 | |
10th | Mission Bio 2014, San Francisco (United States), Series C | Provider of single cell multiomics platform for genotypic and phenotypic analysis | $120M | 65/100 | |
36th | IsoPlexis 2012, New Haven (United States), Acquired | Developer of multiplexed single-cell analysis tools for the diagnostics and life science research | $186M | 52/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on IsoPlexis's competitors? Click here to see the top ones
IsoPlexis's Investments and acquisitions
IsoPlexis has made no investments or acquisitions yet.
Reports related to IsoPlexis
Here is the latest report on IsoPlexis's sector:
News related to IsoPlexis
Filter this list•
Weiss Law Reminds AJRD, SAL, MPB, and ISO Shareholders About Its Ongoing InvestigationsPR Newswire•Mar 02, 2023•Weisslawllp, Aerojet Rocketdyne Holdings, Salisbury Bank, Mid Penn Bank and 1 other
•
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IsoPlexis CorporationBusiness Wire•Feb 15, 2023•IsoPlexis, Kahn Swick & Foti, Berkeley Lights
•
Halper Sadeh LLC Investigates ATCX, MAXR, DCT, ISOGlobeNewswire•Feb 01, 2023•Halper Sadeh, Atlas, Duck Creek, IsoPlexis and 1 other
•
Moore Kuehn Encourages ATCX, DCT, ISO, and MAXAR Investors to Contact Law FirmGlobeNewswire•Feb 01, 2023•Atlas, IsoPlexis, Moore Kuehn, Duck Creek
•
•
The M&A Class Action Firm Continues Investigating the Merger - AJRD, QUMU, ISO, MAXRPR Newswire•Dec 31, 2022•Monteverde, Aerojet Rocketdyne Holdings, Qumu, IsoPlexis and 1 other
•
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed SaACROFAN•Dec 29, 2022•Kahn Swick & Foti, IsoPlexis
•
Halper Sadeh LLC Investigates QUMU, MPB, BLI, ISOPR Newswire•Dec 28, 2022•Halper Sadeh, Qumu, Mid Penn Bank, Berkeley Lights and 1 other
•
Rigrodsky Law, P.A. Is Investigating IsoPlexis Corporation BuyoutThe Wall Street Journal•Dec 23, 2022•Rigrodsky Law, Berkeley Lights, IsoPlexis
•
Isoplexis surges 44% as Berkeley Lights to acquire company for $57.8MSeeking Alpha•Dec 22, 2022•IsoPlexis, Berkeley Lights
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about IsoPlexis
Explore our recently published companies
- Persistent Petrochem - Mumbai based, 2022 founded, Unfunded company
- SoftTalk - Noida based, 2026 founded, Unfunded company
- Gravity Base - Dubai based, 2014 founded, Unfunded company
- Terablaz Media - Ahmedabad based, 2023 founded, Unfunded company
- Way2Max - Jaipur based, 2021 founded, Unfunded company
- IATrain - Picos based, 2024 founded, Unfunded company
